What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Search
Veterinary oncology - cancer treatment
Our R&D team's efforts toward finding new cancer treatments for pets
Tackling NCDs through innovation AND collaboration
Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them
AI&Data Science Fellowship Tuebingen
AI&Data Science Fellowship Tuebingen
Solid Fundations | Bioxcellence | Boehringer Ingelheim
Discover BioXcellence's innovative biopharmaceutical contract manufacturing services, built on a proven track record & solid foundation. Explore now!
AMR_Action_Fund
Boehringer Ingelheim joins AMR Action Fund to support antibiotic R&D
Health for all: How can we contribute to inclusive access?
What drives us to improve the health of humans and animals worldwide
About Boehringer Ingelheim Partnering Days
Find out more about our partnering days and how we can work together to accelerate your science
BI_X_Shanghai
Boehringer Ingelheim opens a second branch of its digital lab in Shanghai
Boehringer Ingelheim acquires a stake in SoundTalks
Boehringer Ingelheim acquires stake in SoundTalks NV, begins pilot programme
Boehringer Ingelheim partners with GNA Biosolutions
Boehringer Ingelheim partners with GNA Biosolutions to develop African swine fever diagnostic test.
The Boehringer Ingelheim Veterinary Scholars Program
The aim of the Boehringer Ingelheim Veterinary Scholars Program is to expose students to biomedical research
Our Vision
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
Moving towards a rabies-free Southeast Asia
Boehringer Ingelheim, in collaboration with Eco-Business, has published a comprehensive whitepaper to stop rabies.
Keep water clean
Human beings can’t survive without water. Further, the safe production of medicines depends on clean drinking water.
Innovation and drone delivery
Addressing healthcare disparities through collaborative innovation and drone delivery
Agreement-to-acquire-Labor-Dr.-Merk
Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
Retinal health: All eyes on vision loss
Discover how we want to prevent vision loss caused by diabetic retinopathy and other retinal diseases
A Clear Vision
Our vision is a future where earlier detection and individualized treatment will stop vision loss in its tracks, protecting and preserving eyesight, and way of life.
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
Research Beyond Borders overview
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.
Supporting Rabies Free Pakistan Indus Hospital
Rabies endangers thousands of human lives in Pakistan every year. We provide green collars and vaccines to improve situation.
FDA Grants Breakthrough Status to Schizophrenia Treatment
Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic
ArisGlobal acquires Boehringer Ingelheim technology
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
Equestrian sports horse health awareness Alex Hua Tian
Together with Olympian trailblazer and eventer Alex Hua Tian, we educate about equine health in China.